Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2017

Chen Chien-Wei, Kuo Chin-Wei, Chen Yi-Lin, Ho Chung-Liang, Su Wu-Chou, Lin Chien-Chung

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds
Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Piperazines

Share to Pyrimidines

Share to Remission Induction

Source

Identifiers

PMID: 28532566
DOI: 10.1016/j.jtho.2017.02.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.PMID 28532566Read ↗

Preclinical Evidence and Clinical Cases of Azd9291 Activity in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc) Brain Metastases (Bm)Semantic proximity Read ↗

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studiesSemantic proximity Read ↗

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment.Semantic proximity Read ↗

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.Semantic proximity Read ↗

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Semantic proximity Read ↗

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.Semantic proximity Read ↗

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.Semantic proximity Read ↗

AZD3759 for CNS metastases in EGFR-mutant lung cancer.Semantic proximity Read ↗

Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non-Small Cell Lung Cancer With ATM Mutation: A Case Report.Semantic proximity Read ↗

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.Semantic proximity Read ↗

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.Semantic proximity Read ↗

Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.